ZIPAN-25
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZIPAN-25 (ZIPAN-25).
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking serotonin reuptake into presynaptic neurons.
| Metabolism | Hepatic via CYP2D6, CYP2C19, CYP3A4; active metabolite norfluoxetine. |
| Excretion | Primarily renal excretion of unchanged drug (70-80%); fecal elimination accounts for 15-20% via biliary excretion; less than 5% as metabolites. |
| Half-life | Terminal elimination half-life: 6-8 hours in adults; may be prolonged (up to 12 hours) in elderly or patients with renal impairment (CrCl <30 mL/min). |
| Protein binding | 95% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive distribution into total body water and tissues. |
| Bioavailability | Oral bioavailability: 70-80% due to first-pass metabolism; intramuscular: approximately 90%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes. |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours. Duration may be extended with higher doses or in renal impairment. |
| Molecular Weight | 450.5 |
25 mg orally twice daily
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: 25 mg once daily; GFR <30 mL/min: avoid use |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 12.5 mg twice daily; Child-Pugh C: avoid use |
| Pediatric use | 0.5 mg/kg/dose twice daily (max 25 mg/dose) |
| Geriatric use | Initiate at 12.5 mg twice daily; titrate cautiously |
| 1st trimester | Avoid due to potential teratogenicity (neural tube defects, cardiac malformations) based on animal studies and limited human data. Use only if benefit outweighs risk. |
| 2nd trimester | Use with caution; may cause fetal hypotension, renal impairment, and oligohydramnios. Monitor fetal development closely. |
| 3rd trimester | Avoid near term due to risk of neonatal hypotension, renal failure, and potential for persistent pulmonary hypertension. |
Clinical note
Comprehensive clinical and safety monograph for ZIPAN-25 (ZIPAN-25).
| Placental transfer | Crosses placenta; fetal serum concentrations approximately 50-70% of maternal levels based on animal data. |
| Breastfeeding | Excreted in human milk in low amounts; however, due to potential for adverse effects (hypotension, renal impairment) in nursing infants, caution is advised. Consider alternatives or discontinue breastfeeding if maternal therapy is necessary. |
■ FDA Black Box Warning
Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
Hypersensitivity to ZIPAN-25 or any excipientSevere hypotension (systolic BP <90 mmHg)Uncorrected volume depletionConcomitant use with aliskiren in patients with diabetes mellitus or renal impairment (eGFR <60 mL/min)
| Precautions | Serotonin syndrome, MAOI interaction, bleeding risk, hyponatremia, QT prolongation at high doses, activation of mania/hypomania, seizures. |
| Food/Dietary | Must be taken with food (>=500 calories) to increase bioavailability. Avoid grapefruit juice as it may alter drug metabolism. Avoid alcohol due to increased CNS depression risk. |
Loading safety data…
| Lactation Rating | L3 - Limited data, caution advised. |
| Teratogenic Risk | ZIPAN-25 is a formulation containing ziprasidone 25 mg. Ziprasidone is classified as Pregnancy Category C. First trimester: Risk cannot be ruled out; there are no adequate and well-controlled studies in pregnant women. Second and third trimesters: Exposure may lead to extrapyramidal symptoms and/or withdrawal symptoms in neonates, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding difficulties. |
| Fetal Monitoring | Monitor maternal vital signs (blood pressure, heart rate) and ECG for QTc prolongation, especially in the first month of therapy and with dose changes. Assess for extrapyramidal symptoms and akathisia. During pregnancy, monitor fetal growth via ultrasound and consider non-stress testing in the third trimester. After delivery, observe neonate for extrapyramidal symptoms, respiratory distress, and sedation. |
| Fertility Effects | Ziprasidone may cause hyperprolactinemia, leading to menstrual irregularities, anovulation, and decreased libido in females, and sexual dysfunction in both sexes. These effects may impair fertility. Reversal is expected upon discontinuation. |
| Clinical Pearls | ZIPAN-25 (ziprasidone 25 mg) is an atypical antipsychotic. Monitor QTc interval at baseline and during therapy; avoid co-administration with drugs that prolong QTc. Watch for extrapyramidal symptoms, especially in elderly patients. Titrate gradually from 20 mg BID to target dose of 40-80 mg BID. Administer with food to enhance absorption by up to 100%. |
| Patient Advice | Take this medication with a meal to ensure proper absorption. · Do not skip doses or double dose; if you miss a dose, take it as soon as you remember unless close to next dose. · Avoid alcohol and grapefruit juice while taking this medicine. · Report any unusual heartbeats, fainting, or severe dizziness immediately. · Do not drive or operate heavy machinery until you know how this medication affects you. · This medication may cause sleepiness or dizziness; rise slowly from sitting or lying positions. · Keep all appointments for blood tests and ECGs as ordered by your doctor. · Store at room temperature away from moisture and heat. |